Hmdb loader
Survey
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:49 UTC
Update Date2022-03-07 02:51:38 UTC
HMDB IDHMDB0014490
Secondary Accession Numbers
  • HMDB14490
Metabolite Identification
Common NameAlfuzosin
DescriptionAlfuzosin is only found in individuals that have used or taken this drug. It is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia ]Alfuzosin is a non-subtype specific alpha(1)-adrenergic blocking agent that exhibits selectivity for alpha(1)-adrenergic receptors in the lower urinary tract. Inhibition of these adrenoreceptors leads to the relaxation of smooth muscle in the bladder neck and prostate, resulting in the improvement in urine flow and a reduction in symptoms in benign prostate hyperplasia. Alfuzosin also inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Structure
Data?1582753185
Synonyms
ValueSource
AlfuzosinaChEBI
AlfuzosineChEBI
AlfuzosinumChEBI
XatralKegg
AlfusosineHMDB
N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamideHMDB
UroXatralHMDB
AlfusozineHMDB
UrionHMDB
Alfuzosin hydrochlorideHMDB
AlphuzosineHMDB
AlfetimHMDB
BenestanHMDB
Chemical FormulaC19H27N5O4
Average Molecular Weight389.4488
Monoisotopic Molecular Weight389.206304377
IUPAC NameN-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide
Traditional Namealfuzosin
CAS Registry Number81403-80-7
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1
InChI Identifier
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
InChI KeyWNMJYKCGWZFFKR-UHFFFAOYSA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazanaphthalenes
Sub ClassBenzodiazines
Direct ParentQuinazolinamines
Alternative Parents
Substituents
  • Quinazolinamine
  • Anisole
  • Dialkylarylamine
  • Alkyl aryl ether
  • Aminopyrimidine
  • Pyrimidine
  • Imidolactam
  • Benzenoid
  • Heteroaromatic compound
  • Tetrahydrofuran
  • Carboximidic acid
  • Carboximidic acid derivative
  • Dialkyl ether
  • Ether
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Organonitrogen compound
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic nitrogen compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
RoleNot Available
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.28 g/LNot Available
LogP1.4Not Available
Experimental Chromatographic Properties

Experimental Collision Cross Sections

Adduct TypeData SourceCCS Value (Å2)Reference
[M+H]+CBM194.630932474
[M+H]+Not Available193.903http://allccs.zhulab.cn/database/detail?ID=AllCCS00001056
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.28 g/LALOGPS
logP2.02ALOGPS
logP1.19ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)14.64ChemAxon
pKa (Strongest Basic)7.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area111.83 ŲChemAxon
Rotatable Bond Count8ChemAxon
Refractivity107.11 m³·mol⁻¹ChemAxon
Polarizability42.71 ųChemAxon
Number of Rings3ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DarkChem[M+H]+190.79431661259
DarkChem[M-H]-188.55631661259
DeepCCS[M+H]+187.12630932474
DeepCCS[M-H]-184.76830932474
DeepCCS[M-2H]-219.03530932474
DeepCCS[M+Na]+194.26330932474
AllCCS[M+H]+193.032859911
AllCCS[M+H-H2O]+190.532859911
AllCCS[M+NH4]+195.432859911
AllCCS[M+Na]+196.032859911
AllCCS[M-H]-191.232859911
AllCCS[M+Na-2H]-191.832859911
AllCCS[M+HCOO]-192.732859911

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
AlfuzosinCOC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO14024.5Standard polar33892256
AlfuzosinCOC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO13408.8Standard non polar33892256
AlfuzosinCOC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO13622.7Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Alfuzosin,1TMS,isomer #1COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C)=C2C=C1OC3668.6Semi standard non polar33892256
Alfuzosin,1TMS,isomer #1COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C)=C2C=C1OC3270.9Standard non polar33892256
Alfuzosin,1TMS,isomer #1COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C)=C2C=C1OC5231.1Standard polar33892256
Alfuzosin,1TMS,isomer #2COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N)=C2C=C1OC3539.2Semi standard non polar33892256
Alfuzosin,1TMS,isomer #2COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N)=C2C=C1OC3303.0Standard non polar33892256
Alfuzosin,1TMS,isomer #2COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N)=C2C=C1OC5275.9Standard polar33892256
Alfuzosin,2TMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N[Si](C)(C)C)=C2C=C1OC3595.1Semi standard non polar33892256
Alfuzosin,2TMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N[Si](C)(C)C)=C2C=C1OC3322.6Standard non polar33892256
Alfuzosin,2TMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N[Si](C)(C)C)=C2C=C1OC4837.1Standard polar33892256
Alfuzosin,2TMS,isomer #2COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC3563.9Semi standard non polar33892256
Alfuzosin,2TMS,isomer #2COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC3281.4Standard non polar33892256
Alfuzosin,2TMS,isomer #2COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC4790.3Standard polar33892256
Alfuzosin,3TMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC3527.8Semi standard non polar33892256
Alfuzosin,3TMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC3341.6Standard non polar33892256
Alfuzosin,3TMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C)=NC(N([Si](C)(C)C)[Si](C)(C)C)=C2C=C1OC4427.3Standard polar33892256
Alfuzosin,1TBDMS,isomer #1COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC3841.9Semi standard non polar33892256
Alfuzosin,1TBDMS,isomer #1COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC3457.9Standard non polar33892256
Alfuzosin,1TBDMS,isomer #1COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC5122.6Standard polar33892256
Alfuzosin,1TBDMS,isomer #2COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N)=C2C=C1OC3727.1Semi standard non polar33892256
Alfuzosin,1TBDMS,isomer #2COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N)=C2C=C1OC3487.0Standard non polar33892256
Alfuzosin,1TBDMS,isomer #2COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N)=C2C=C1OC5212.1Standard polar33892256
Alfuzosin,2TBDMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC3923.0Semi standard non polar33892256
Alfuzosin,2TBDMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC3681.8Standard non polar33892256
Alfuzosin,2TBDMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N[Si](C)(C)C(C)(C)C)=C2C=C1OC4771.3Standard polar33892256
Alfuzosin,2TBDMS,isomer #2COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC3954.5Semi standard non polar33892256
Alfuzosin,2TBDMS,isomer #2COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC3712.7Standard non polar33892256
Alfuzosin,2TBDMS,isomer #2COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC4731.1Standard polar33892256
Alfuzosin,3TBDMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC4065.5Semi standard non polar33892256
Alfuzosin,3TBDMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC3907.3Standard non polar33892256
Alfuzosin,3TBDMS,isomer #1COC1=CC2=NC(N(C)CCCN(C(=O)C3CCCO3)[Si](C)(C)C(C)(C)C)=NC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=C2C=C1OC4486.3Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Alfuzosin GC-MS (Non-derivatized) - 70eV, Positivesplash10-00fr-9244000000-7f0f72006d4f335adfd02017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Alfuzosin GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOFsplash10-000i-0009000000-b390e2d32ee38fb79cf92017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOFsplash10-00dr-0039000000-1058f618ea52b7aa95e62017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOFsplash10-0aos-0195000000-97624e7dcce906c3a1ee2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOFsplash10-0udi-0391000000-6d58b29a79c5af2627232017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOFsplash10-0udi-1970000000-b3cb9821b3584d86539f2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOFsplash10-0i6s-1920000000-50ca3c071a5548796b3a2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOFsplash10-014i-5900000000-b3a86e227650a23790ec2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOFsplash10-014i-9400000000-9929aaf0359abea0c1662017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , negative-QTOFsplash10-014i-9100000000-b3dba930d4cfe0d28a8e2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOFsplash10-0006-0009000000-58fd75abdf178ea1b3312017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOFsplash10-0006-0119000000-90a7799e494035d224e72017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOFsplash10-0abi-5791000000-648d5529faeac9e35dc02017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOFsplash10-00di-9260000000-591f2bacf7d82aeba7e32017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOFsplash10-00di-9250000000-d107a0e9675604325bb12017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOFsplash10-00di-9340000000-f708562f3998488d7fce2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOFsplash10-00di-7910000000-3fe44ce2a42f727569e22017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOFsplash10-05fr-8900000000-dca38c682ad0b6c90b462017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin LC-ESI-QFT , positive-QTOFsplash10-0bvl-9300000000-bad5c36d48e0e93a82aa2017-09-14HMDB team, MONAView Spectrum
Experimental LC-MS/MSLC-MS/MS Spectrum - Alfuzosin , positive-QTOFsplash10-0006-0249000000-93552ff8c72ff220f1722017-09-14HMDB team, MONAView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Alfuzosin 10V, Positive-QTOFsplash10-0006-0092000000-4b7c2dae5894c14b85752016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Alfuzosin 20V, Positive-QTOFsplash10-006x-1090000000-a62c896d99f7b9d73c0a2016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Alfuzosin 40V, Positive-QTOFsplash10-000i-3090000000-381d1c6c96f3e65c44e02016-08-02Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Alfuzosin 10V, Negative-QTOFsplash10-000i-1139000000-3af55917407f4facdb0b2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Alfuzosin 20V, Negative-QTOFsplash10-00yi-4193000000-b8b9ec6006943f78ab012016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Alfuzosin 40V, Negative-QTOFsplash10-017i-6390000000-a64c36b6d4e976a6272f2016-08-03Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00346 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB00346 details
Abnormal Concentrations
Not Available
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB00346
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID2008
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkAlfuzosin
METLIN IDNot Available
PubChem Compound2092
PDB IDNot Available
ChEBI ID51141
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046 ]
  2. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574 ]
  3. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253 ]
  4. Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. [PubMed:7682910 ]
  5. McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. [PubMed:11893233 ]

Enzymes

General function:
Involved in monooxygenase activity
Specific function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide.
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular weight:
57255.585
References
  1. Guay DR: Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14-23. [PubMed:15555475 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular weight:
51486.0
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. [PubMed:8799556 ]
  3. Lee M: Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm. 2003 Jul 15;60(14):1426-39. [PubMed:12892027 ]
  4. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046 ]
  5. Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13. [PubMed:15639685 ]
  6. Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther. 1997 Jul;282(1):228-35. [PubMed:9223558 ]
  7. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605. [PubMed:8196478 ]
  8. Beique L, Por CP, Evans MF: Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia? Can Fam Physician. 1998 Dec;44:2659-62. [PubMed:9870119 ]
  9. McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8. [PubMed:16613526 ]
  10. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574 ]
  11. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol- calcium second messenger system
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular weight:
56835.4
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. [PubMed:8799556 ]
  3. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046 ]
  4. Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13. [PubMed:15639685 ]
  5. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605. [PubMed:8196478 ]
  6. Beique L, Por CP, Evans MF: Are the new selective alpha-blockers better than non-selective alpha-blockers for benign prostatic hyperplasia? Can Fam Physician. 1998 Dec;44:2659-62. [PubMed:9870119 ]
  7. McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8. [PubMed:16613526 ]
  8. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574 ]
  9. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253 ]
General function:
Involved in G-protein coupled receptor protein signaling pathway
Specific function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular weight:
60462.2
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM: Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. [PubMed:8799556 ]
  3. Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [PubMed:9122046 ]
  4. Lowe FC: Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther. 2004 Nov;26(11):1701-13. [PubMed:15639685 ]
  5. Faure C, Pimoule C, Vallancien G, Langer SZ, Graham D: Identification of alpha 1-adrenoceptor subtypes present in the human prostate. Life Sci. 1994;54(21):1595-605. [PubMed:8196478 ]
  6. McVary KT: BPH: epidemiology and comorbidities. Am J Manag Care. 2006 Apr;12(5 Suppl):S122-8. [PubMed:16613526 ]
  7. Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [PubMed:16553574 ]
  8. Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [PubMed:11750253 ]